Nienke Soeters1, Erik van Bussel2, Rikkert van der Valk2, Allegonda Van der Lelij2, Nayyirih G Tahzib2. 1. From the Utrecht Cornea Research Group (Soeters, van Bussel, van der Valk, Van der Lelij), Department of Ophthalmology, University Medical Center Utrecht, Utrecht, and Zonnestraal Eye Hospital (Tahzib), Amersfoort, the Netherlands. Electronic address: n.soeters@umcutrecht.nl. 2. From the Utrecht Cornea Research Group (Soeters, van Bussel, van der Valk, Van der Lelij), Department of Ophthalmology, University Medical Center Utrecht, Utrecht, and Zonnestraal Eye Hospital (Tahzib), Amersfoort, the Netherlands.
Abstract
PURPOSE: To compare central corneal thickness (CCT) with and without using an eyelid speculum during corneal collagen crosslinking (CXL). SETTING: University Medical Center Utrecht, Utrecht, the Netherlands. DESIGN: Prospective nonrandomized comparative study. METHODS: Eyes with progressive keratoconus were treated by CXL and consecutively divided into 2 groups. In Group A, an eyelid speculum remained in place throughout the entire CXL procedure. In Group B, the eyelids remained closed during the 30-minute riboflavin instillation. Intraoperative ultrasound pachymetry measurements were performed at different timepoints. The visual acuity, refraction, keratometry, pachymetry, and endothelium were evaluated 6 months after CXL. The main outcome measures were intraoperative CCT measurements and the clinical CXL effect after 6 months. RESULTS: Fifty-two eyes (50 patients) were treated. After riboflavin instillation, a statistically significant difference in CCT reduction was found between the 2 groups (P<.001), with a mean CCT decrease of 62 μm±53 (SD) (13%±11%) in Group A and 11±35 μm (2%±8%) in Group B. No statistically significant between-group differences were found after epithelial removal or ultraviolet-A (UVA) irradiation. Six months after CXL, no statistically significant between-group difference was found in the visual acuity, refraction, keratometry, pachymetry, or endothelium. CONCLUSIONS: Avoidance of an eyelid speculum during riboflavin instillation resulted in less CCT reduction during CXL. This finding could increase the chance of attaining the required pachymetry safety margin for applying UVA and thus decrease the chance of premature CXL treatment termination. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.
PURPOSE: To compare central corneal thickness (CCT) with and without using an eyelid speculum during corneal collagen crosslinking (CXL). SETTING: University Medical Center Utrecht, Utrecht, the Netherlands. DESIGN: Prospective nonrandomized comparative study. METHODS: Eyes with progressive keratoconus were treated by CXL and consecutively divided into 2 groups. In Group A, an eyelid speculum remained in place throughout the entire CXL procedure. In Group B, the eyelids remained closed during the 30-minute riboflavin instillation. Intraoperative ultrasound pachymetry measurements were performed at different timepoints. The visual acuity, refraction, keratometry, pachymetry, and endothelium were evaluated 6 months after CXL. The main outcome measures were intraoperative CCT measurements and the clinical CXL effect after 6 months. RESULTS: Fifty-two eyes (50 patients) were treated. After riboflavin instillation, a statistically significant difference in CCT reduction was found between the 2 groups (P<.001), with a mean CCT decrease of 62 μm±53 (SD) (13%±11%) in Group A and 11±35 μm (2%±8%) in Group B. No statistically significant between-group differences were found after epithelial removal or ultraviolet-A (UVA) irradiation. Six months after CXL, no statistically significant between-group difference was found in the visual acuity, refraction, keratometry, pachymetry, or endothelium. CONCLUSIONS: Avoidance of an eyelid speculum during riboflavin instillation resulted in less CCT reduction during CXL. This finding could increase the chance of attaining the required pachymetry safety margin for applying UVA and thus decrease the chance of premature CXL treatment termination. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.
Authors: R Ghaffari; M Mortazavi; P Anvari; A Salamat Rad; F Alipour; F Hafezi; S Asgari; H Hashemi Journal: Eye (Lond) Date: 2017-11-24 Impact factor: 3.775
Authors: Ahmed M Sherif; Nihal A El-Gheriany; Yehia M Salah El-Din; Lamiaa S Aly; Amr A Osman; Michael A Grentzelos; George D Kymionis Journal: J Ophthalmol Date: 2016-01-13 Impact factor: 1.909
Authors: Carlo Cagini; F Riccitelli; M Messina; F Piccinelli; G Torroni; D Said; A Al Maazmi; H S Dua Journal: Int Ophthalmol Date: 2020-08-13 Impact factor: 2.031